Amin bispecific antibody efficacy significantly better than chemotherapy stage 3 trial early termination

Acute lymphoblastic leukemia (ALL) is the most common leukemia in children, and B-cell ALL makes children more susceptible to infection because cancerous B cells do not function properly with their immune functionAlthough existing therapies can cure most ALL patients, their prognosis decreases rapidly once they relapse, especially in high-risk ALL patientsBlincyto is a BiTE developed by Amgen, which combines one end with CD19 antigens expressed on the surface of B cells and CD3 receptors on the surface of T cells on the otherIt can raise T-cells near cancer cells, promoting their killing of cancer cellsBlincyto has received FDA approval to treat patients with relapsed/incurable B-cell ALLIt also received accelerated FDA approval to treat patients with B-cell ALL with micro-residual disease (MRD) greater than 0.1%in an open label called 20120215, in randomized, global 3 trials, high-risk first-time b-cell ALL patients received treatment with Blincyto or standard consolidation chemotherapyThe primary endpoint of the experiment is event-free survivalThe test results show that Blincyto reached the main end of the experimentBased on the recommendations of the Independent Data Monitoring Board (DMC), Amin terminated the patient registration for the trial in advance, and follow-up follow-up will continue to follow the trial process, in a randomized Phase 3 clinical trial called AALL1331, amation will stop entering the group of high-risk and mid-critical B-cell ALL children with the recommendation of DMCThe DMC's recommendations are based on a significant trend in improving disease-free survival, total survival, MRD, and toxic side effects compared to chemotherapy" the results were excellent, taken togetherChildren and adolescents in ALL patients have poor prognosis after relapseThey still need more treatment options, especially for high-risk patients," said DrDavid MReese, executive vice president of research and development at Amin References:® Retrieved September 24, 2019, from https://